난소 제거된 쥐의 두개골 결손에서 bisphosphonate와 parathyroid hormone 전신 투여 후 골 재생 평가
Bone Regeneration Assessment after Systemic Injection of Bisphosphonate and Parathyroid Hormone in the Ovariectomized Rat Calvarial Defect
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Although there are many studies comparing the individual effects of zoledronic acid and teriparatide in bone grafting in an osteoporotic environment, the combined effect is not well known. The purpose of this study was to compare the effects of systemic administration of zoledronic acid and teriparatide on bone regeneration at the bone graft site after bone grafting to the cranium defect in rats with osteoporosis induced by ovariectomy. Thirty-nine rats were randomly divided into 8 groups (sham ovariectomy group [sOVX, n=4]; Control group [CONT, n=5]; sham zoledronic acid group [sZA, n=5]; sham teriparatide group [sTPD, n=5]; sham zoledronic acid and sham teriparatide group [sZATPD, n=5]; zoledronic acid group [ZA, n=5]; teriparatide group [TPD, n=5]; zoledronic acid and sham teriparatide group [ZA-TPD, n=5]). A critical size defect with a diameter of 5 mm was formed on both craniums of osteoporosisinduced rats, and bone grafting was performed on only one side. The defect on both sides was covered with a collagen membrane. After bone grafting, zoledronic acid and teriparatide were administered, and all animals were sacrificed 6 weeks after bone grafting. Specimens were subjected to micro-computed tomography and histological analysis. As a result of micro-computed tomography analysis, bone mineral density in the tibia was the highest in the ZA-TPD group, followed by the zoledronic acid and teriparatide groups. Residual graft material at the site where bone grafting was performed was the highest in the TPD group, and new bone increased in the order of CONT, ZA, TPD, and ZATPD groups. The TPD group had the most new bone in the area where bone grafting was not performed, and the CONT group had the biggest BS/BV, but there was no statistically significant difference. As a result of histological morphological analysis, the remaining graft material in the bone graft site decreased in the order of CONT, ZA, TPD, and ZA-TPD groups, and the new bone increased in the order of ZA, ZA-TPD, CONT, and TPD groups. The amount of new bone in the areas where bone grafting was not performed increased in the order of ZA, CONT, TPD, and ZA-TPD groups, and the CONT and TPD groups showed a statistically significant difference from the ZA-TPD group. Zoledronic acid and teriparatide showed differences in bone regeneration at the parietal bone graft site, and the combination of the two drugs was more effective in bone regeneration.
Abstract
Although there are many studies comparing the individual effects of zoledronic acid and teriparatide in bone grafting in an osteoporotic environment, the combined effect is not well known. The purpose of this study was to compare the effects of systemic administration of zoledronic acid and teriparatide on bone regeneration at the bone graft site after bone grafting to the cranium defect in rats with osteoporosis induced by ovariectomy. Thirty-nine rats were randomly divided into 8 groups (sham ovariectomy group [sOVX, n=4]; Control group [CONT, n=5]; sham zoledronic acid group [sZA, n=5]; sham teriparatide group [sTPD, n=5]; sham zoledronic acid and sham teriparatide group [sZATPD, n=5]; zoledronic acid group [ZA, n=5]; teriparatide group [TPD, n=5]; zoledronic acid and sham teriparatide group [ZA-TPD, n=5]). A critical size defect with a diameter of 5 mm was formed on both craniums of osteoporosisinduced rats, and bone grafting was performed on only one side. The defect on both sides was covered with a collagen membrane. After bone grafting, zoledronic acid and teriparatide were administered, and all animals were sacrificed 6 weeks after bone grafting. Specimens were subjected to micro-computed tomography and histological analysis. As a result of micro-computed tomography analysis, bone mineral density in the tibia was the highest in the ZA-TPD group, followed by the zoledronic acid and teriparatide groups. Residual graft material at the site where bone grafting was performed was the highest in the TPD group, and new bone increased in the order of CONT, ZA, TPD, and ZATPD groups. The TPD group had the most new bone in the area where bone grafting was not performed, and the CONT group had the biggest BS/BV, but there was no statistically significant difference. As a result of histological morphological analysis, the remaining graft material in the bone graft site decreased in the order of CONT, ZA, TPD, and ZA-TPD groups, and the new bone increased in the order of ZA, ZA-TPD, CONT, and TPD groups. The amount of new bone in the areas where bone grafting was not performed increased in the order of ZA, CONT, TPD, and ZA-TPD groups, and the CONT and TPD groups showed a statistically significant difference from the ZA-TPD group. Zoledronic acid and teriparatide showed differences in bone regeneration at the parietal bone graft site, and the combination of the two drugs was more effective in bone regeneration.
참고문헌 (35)
- Jung UW, "The effect of varying the particle size of beta tricalcium phosphate carrier of recombinant human bone morphogenetic protein-4 on bone formation in rat calvarial defects", J Periodontol, 77, pp.765~772 (2006)
- on calvarial bone graft in irradiated rat, "Oral Dis", 2019, 822~830
- Park KM, "Bone Regeneration Effect of Hyperbaric Oxygen Therapy Duration on Calvarial Defects in Irradiated Rats", Biomed Res Int, 2019, pp.9051713~ (2019)
- Dam C, "Effect of teriparatide on early sinus graft healing in the ovariectomized rabbit", Clin Oral Implants Res, 31, pp.264~273 (2020)
- Albright F, "Postmenopausal Osteoporosis : Its Clinical Features", JAMA, 116, pp.2465~2474 (1941)
- Watts NB, "American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis", Endocr Pract, (16Suppl 3), pp.1~37 (2010)
- Hauk L, "American College of O, Gynecologists. ACOG releases practice bulletin on osteoporosis", Am Fam Physician, 88, pp.269~275 (2013)
- Compston J, "Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK : National Osteoporosis Guideline Group(NOGG)update 2013", Maturitas, 75, pp.392~396 (2013)
- Eriksen EF, "Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis : a systematic review", Bone, 58, pp.126~135 (2014)
- Serrano AJ, "Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis", Gynecol Endocrinol, 29, pp.1005~1014 (2013)
- Gauthier K, "Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis: Clinical Effectiveness and Harms", ~ (2012)
- Kanis JA, "European guidance for the diagnosis and manage ment of osteoporosis in postmenopausal women", Osteoporos Int, 24, pp.23~57 (2013)
- Huh J, "Parathyroid Hormone(1-34)Might Not Improve Early Bone Healing after Sinus Augmentation in Healthy Rabbits", Biomed Res Int, 2017, pp.6087676~ (2017)
- Jilka RL, "Molecular and cellular mechanisms of the anabolic effect of intermittent PTH", Bone, 40, pp.1434~1446 (2007)
- Murphy CM, "PTH(1-34)Treatment Increases Bisphosphonate Turnover in Fracture Repair in Rats", J Bone Miner Res, 30, pp.1022~1029 (2015)
- Yousefzadeh N, "Ovariectomized rat model of osteoporosis : a practical guide", EXCLI J, 19, pp.89~107 (2020)
- Sung Bae Park, "Bone Mineral Density Changes after Ovariectomy in Rats as an Osteopenic Model : Stepwise Description of Double Dorso-Lateral Approach", 대한신경외과학회지, 48(4), pp.309~312 (2010), 대한신경외과학회
- Turner RT, "Animal models for osteoporosis", Rev Endocr Metab Disord, 2, pp.117~127 (2001)
- Turner AS, "Animal models of osteoporosis--necessity and limitations", Eur Cell Mater, 1, pp.66~81 (2001)
- Komori T, "Animal models for osteoporosis", Eur J Pharmacol, 759, pp.287~294 (2015)
- in postmenopausal osteoporosis, "J Bone Miner Res", 2011, 503~511
- Yun JI, "Effect of systemic parathyroid hormone(1-34)and a beta-tricalcium phosphate biomaterial on local bone formation in a criticalsize rat calvarial defect model", J Clin Periodontol, 37, pp.419~426 (2010)
- Hyo Won Jang, "Development of animal model for Bisphosphonates-related osteonecrosis of the jaw (BRONJ)", Maxillofacial Plastic Reconstructive Surgery, 37(7), pp.1~7 (2015), 대한악안면성형재건외과학회[DOI]
- Hoffmann DB, "Comparison of parathyroid hormone and strontium ranelate in combination with whole-body vibration in a rat model of osteoporosis", J Bone Miner Metab, 35, pp.31~39 (2017)
- Zandi M, "Effect of different doses and durations of teriparatide therapy on resolution of medication-related osteonecrosis of the jaw: A randomized, controlled preclinical study in rats", J Craniomaxillofac Surg, 46, pp.466~472 (2018)
- Bolette A, "Influence of induced infection in medication-related osteonecrosis of the jaw development after tooth extraction : A study in rats", J Craniomaxillofac Surg, 47, pp.349~356 (2019)
- Kim JY, "Effects of pre-extraction intermittent PTH administration on extraction socket healing in bisphosphonate administered ovariectomized rats", Sci Rep, 11, pp.54~ (2021)
- Hornby SB, "Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats", Calcif Tissue Int, 72, pp.519~527 (2003)
- Croucher PI, "Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival", J Bone Miner Res, 18, pp.482~492 (2003)
- Black DM, "Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis", N Engl J Med, 356, pp.1809~1822 (2007)
- Tsunori K, "Effects of intermittent administration of parathyroid hormone on bone augmentation in rat calvarium", Implant Dent, 24, pp.142~148 (2015)
- Silva ED, "Intermittent administration of parathyroid hormone improves the repairing process of rat calvaria defects : A histomorphometric and radiodensitometric study", Med Oral Patol Oral Cir Bucal, 20, pp.e489~93 (2015)
- Kuroshima S, "Parathyroid hormone related to bone regeneration in grafted and nongrafted tooth extraction sockets in rats", Implant Dent, 22, pp.71~76 (2013)
- Kuroshima S, "Intra-oral PTH administration promotes tooth extraction socket healing", J Dent Res, 92, pp.553~559 (2013)
- Kuroshima S, "Distinctive tooth-extraction socket healing : bisphosphonate versus parathyroid hormone therapy", J Periodontol, 85, pp.24~33 (2014)